Showing results (2241-2250 of 2,345) with videos related to
Sort By:
Pageof 235
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activityH E Shannon, M J Sheardown, F P Bymaster, et al.Nature Communications|April 14, 2017
Regio- and conformational isomerization critical to design of efficient thermally-activated delayed fluorescence emittersMarc K Etherington, Flavio Franchello, Jamie Gibson, et al.Journal of the Air & Waste Management Association (1995)|September 11, 2020
Methane flux from flowback operations at a shale gas siteJacob T Shaw, Grant Allen, Joseph Pitt, et al.Marine Pollution Bulletin|May 31, 2001
ENCORE: the effect of nutrient enrichment on coral reefs. Synthesis of results and conclusionsK Koop, D Booth, A Broadbent, et al.Hepatology (Baltimore, Md.)|November 28, 2012
Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosisRichy C Y Chen, Phornnop Naiyanetr, Shang-An Shu, et al.Biorxiv : the Preprint Server for Biology|April 8, 2024
Repetitive head impacts induce neuronal loss and neuroinflammation in young athletesMorgane L M D Butler, Nida Pervaiz, Kerry Breen, et al.Nature|September 17, 2025
Repeated head trauma causes neuron loss and inflammation in young athletesMorgane L M D Butler, Nida Pervaiz, Kerry Breen, et al.Neurorehabilitation and Neural Repair|March 14, 2012
Theta burst stimulation in the rehabilitation of the upper limb: a semirandomized, placebo-controlled trial in chronic stroke patientsPenelope Talelli, Amanda Wallace, Michelle Dileone, et al.Cancer Discovery|February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid LeukemiaAlan H Shih, Cem Meydan, Kaitlyn Shank, et al.Journal of Medicinal Chemistry|June 4, 1999
1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivativesL Jeppesen, P H Olesen, L Hansen, et al.Pageof 235